Revolutionizing Healthcare: BioTechPharma's Saliva-Based Diagnostics
BioTechPharma Holdings is transforming healthcare screening and drug testing with its groundbreaking saliva-based technology. Our non-invasive approach delivers rapid, accurate, and convenient on-site results, all supported by the precision of our expert laboratory analysis. Experience the future of diagnostics—faster, more comfortable, and more reliable.
Learn More
Healthcare Screening Issues

Time-Consuming Process
Traditional screening methods often involve multiple doctor visits and lab tests, causing significant delays in diagnosis and treatment.

Invasive Methods
Blood and urine tests are invasive procedures that can be uncomfortable and inconvenient for patients.

Privacy Concerns
Current testing methods may compromise patient privacy and dignity, leading to anxieties about confidentiality.

Adulteration Risks
Urine samples are easily manipulated, potentially leading to inaccurate or compromised test results.
BTP's Revolutionary Technology
One-Step Collection
BTP's device simplifies testing with a single saliva sample, collected quickly and easily on-site.
Split-Sample Feature
A sample portion is retained for optional lab verification, ensuring reliable results.
Tamper-Proof Design
The device's design safeguards the sample, preserving test result integrity.
Biometric Identification
Optional fingerprint and DNA capture enhances sample integrity and accurate patient identification, preventing errors.
Saliva Testing Benefits
Early Detection
Saliva tests offer an extended detection window, identifying substances up to four days after ingestion—significantly longer than other methods.
Non-Invasive & Convenient
Patients find saliva testing comfortable and easy, eliminating the need for specialized facilities and offering a superior alternative to blood or urine tests.
Rapid Results
Get results in just 3 minutes—perfect for time-sensitive situations requiring immediate information, such as post-accident or impairment testing.
EZ SALIVA Kits
EZ SALIVA-I: Rapid Results
Get quick, reliable results for various health indicators with our easy-to-use basic kit. Includes a split sample for lab confirmation.
EZ SALIVA-II: Advanced Testing
Unlock deeper insights into patient health with advanced DNA and RNA testing capabilities. Fast and efficient for comprehensive analysis.
EZ SALIVA-III: Complete Health Screening
Experience the ultimate health screening: combining rapid on-site testing with thorough DNA/RNA analysis for a comprehensive overview.
Drug-O-Meter: Digital Testing Platform
Multi-Channel Testing
Analyzes 12-18 reagent strips in under 3 minutes for rapid results.
Versatile Design
Its clipboard format is perfect for law enforcement and healthcare professionals.
Connectivity
Seamless data transfer and analysis via Bluetooth and USB.
Insta-Read: Mobile Application
Smartphone Compatible
Access your test results anytime, anywhere, on both iOS and Android devices.
Cloud-Based Storage
Securely store and easily access your test results in the cloud.
Result Sharing
Share your results effortlessly via email, web, or SMS with healthcare providers or loved ones.
Market Opportunity
$78.5B
Global Diagnostics Market
2023 market size
$27.5B
Point-of-Care Diagnostics
Market segment size
$6.8B
Lateral Flow Assays
Market segment size
$9.75B
Toxicology Testing
Projected market size by 2028
Target Markets

1

Healthcare
Rapid diagnostic testing in hospitals, clinics, and physician offices.

2

Law Enforcement
On-site roadside testing for impaired driving detection.

3

Workplace
Efficient pre-employment and random drug testing programs.

4

Government
Comprehensive applications in border control, military, and security sectors.
Competitive Advantages
Unmatched Speed
Get results in just 3 minutes—significantly faster than competitors' 6+ minute tests.
Exceptional Accuracy
Our tests boast over 97% accuracy, with optional lab confirmation for ultimate reliability.
Tamper-Evident Design
Our innovative kits prevent sample tampering, guaranteeing result integrity.
Cost Savings
Our all-in-one solution eliminates multiple tests and facilities, delivering substantial cost savings.
Intellectual Property
US Patent 8,940,527
Combines sample collection, testing, confirmation, and identification.
US Patent 7,741,103
Fluid sample testing device with integrated subject identification.
US Patent 7,879,623
Device for collecting and testing substances.
US Patent 6,352,863
Assay device based on a nanotechnology platform.
Manufacturing Capabilities
Current Production
BTP's efficient lines produce 4 units per second, ensuring rapid delivery.
Expansion to 50 Million
Ten production lines will yield 50 million units monthly, meeting surging demand.
Unmatched Cost Efficiency
BTP's $26 million investment surpasses competitors' $100 million in output, delivering substantial cost savings.
Management Team
Dr. Raouf Guirguis
Chairman & President, prolific inventor with over 187 patents.
Nate Keele
CEO, driving healthcare innovation through entrepreneurial leadership.
Dr. Les Edinboro
Toxicology Lab Director, bringing 35+ years of expertise.
Advisory Board
Dr. Barry Sample
Medical Device Consultant; former Quest Diagnostics executive with extensive industry experience.
Dr. Randy E. Durbin
Chief Medical Officer; expert in substance use disorders and public health, offering valuable clinical insights.
Financial Projections
These projections demonstrate substantial year-over-year growth in total revenue, gross profits, and EBITDA, projecting a significant increase in profitability over the next three years.
Funding Requirements
Total Raise
BioTechPharma Holdings seeks $50 million in funding to scale operations and drive rapid growth.
Acquisitions
$20 million will be allocated for strategic company acquisitions, expanding the portfolio and capabilities.
Operations
$12.5 million will establish and maintain the company's offices and organizational infrastructure.
R&D and Manufacturing
$15 million will drive research, development, and scaling production to support continued growth.
Exit Strategy
Acquisition Target
BioTechPharma Holdings is well-positioned for acquisition by major laboratory or diagnostics companies seeking to expand their product lines and capabilities.
High-Growth Profile
The company projects 2.5x annual EBITDA growth over the next four years, making it a highly attractive investment for strategic buyers.
Strategic Spin-Off Option
BioTechPharma can strategically separate its rapid diagnostics unit from its laboratory DNA/prognostic division, enabling more focused growth and enhanced operational efficiency.
Healthcare Market Trends

1

Outpatient Care Expansion
Diagnostic and treatment services are increasingly shifting from hospitals to outpatient settings.

2

Molecular Diagnostics Surge
Molecular diagnostics is experiencing the most rapid growth within the diagnostics sector.

3

Cost Reduction Imperative
Healthcare providers face growing pressure to control costs while enhancing patient outcomes, demanding efficient solutions.
Toxicology Market Growth
Current Demand
The toxicology market is experiencing growth fueled by a rising demand for workplace and roadside drug testing.
Regulatory Changes
New Department of Transportation (DOT) regulations now permit saliva testing for roadside drug screening, further expanding market opportunities.
Market Size
The toxicology market is projected to reach a substantial $9.75 billion by 2028, presenting significant growth and investment potential.
Global Illicit Drug Use
Infectious Disease Market
HIV Testing
Sub-Saharan Africa faces a significant challenge: 49% of those with HIV are undiagnosed. Improved testing and awareness campaigns are crucial.
Malaria Risk
Malaria poses a substantial global health threat, affecting 3.2 billion people worldwide.
Influenza Impact
Influenza's severity is underscored by the 40,000 annual deaths it causes in the US alone.
Hepatitis C
The global Hepatitis C burden is immense, with 185 million people currently infected, emphasizing the need for better diagnostics and treatments.
Cardiovascular Disease Market
The cardiovascular disease market is staggering: 17.3 million annual deaths globally underscore its impact, alongside 387 million adults with diabetes. In the US alone, high cholesterol affects 33.5% of the population, with 5.1 million living with heart failure.
Driving Under the Influence Statistics: A Sobering Look
The devastating consequences of driving under the influence (DUI) are far-reaching, impacting individuals, families, and the economy as a whole. The following statistics highlight the urgent need for effective prevention and intervention strategies.
In conclusion, these statistics underscore the critical public health and safety issue of impaired driving. Addressing this problem requires a multifaceted approach involving stricter enforcement, public awareness campaigns, and expanded treatment options.
International Market Opportunities
Australia
Oral fluid testing systems are successfully implemented in Australian law enforcement and border control.
United Kingdom
The UK sees increasing use of rapid testing solutions like "drugalyzers" for drug screening and security.
United States
US law enforcement widely uses oral fluid testing; expansion into border control and security is underway.
Strategic Partnerships

LumiQuick Diagnostics
Joint venture to develop new diagnostic test strips, expanding our product line.

Oasis Diagnostics
Collaboration on R&D for novel tumor markers, improving early cancer detection.

Vantari Genetics
Acquisition target to integrate forensic toxicology and DNA services, broadening our capabilities.
Future Product Development
Multi-Fluid Testing
Expand testing beyond saliva to analyze various bodily fluids for a holistic health assessment.
Early Disease Detection
Develop advanced biomarkers for early diagnosis of serious illnesses like cancer and infectious diseases, enabling timely intervention.
Real-time Drug Monitoring
Provide rapid, near-bedside testing for various drug classes to optimize patient treatment plans.
Competitive Landscape
BTP Advantage
Our saliva-based test delivers results in just 3 minutes, features tamper-proof technology, and includes integrated biometrics for superior security and reliability.
Competitor Limitations
Traditional urine or blood tests take 15-30 minutes, lack robust tamper-proofing, and offer less secure result verification.
Risk Factors
Regulatory Delays
Navigating complex healthcare regulations can cause unforeseen delays, potentially impacting our timeline for achieving key objectives.
Manufacturing Challenges
Scaling production to meet increasing demand presents challenges to quality control and operational efficiency, potentially affecting order fulfillment.
Market Adoption
Widespread adoption of our innovative saliva-based diagnostics may face hurdles, requiring substantial investment in education and marketing to increase market share.
Corporate Social Responsibility
Sustainable Practices
BioTechPharma is committed to environmentally responsible manufacturing, minimizing waste and prioritizing sustainability.
Community Health
We are dedicated to expanding access to diagnostic testing and healthcare in underserved communities.
Global Impact
BioTechPharma strives to address significant global healthcare challenges in developing nations.
Conclusion: A Vision for the Future of Diagnostics

Innovation
We will continue at the forefront of rapid, non-invasive diagnostic technologies.

Growth
Our strategy involves expanding our market reach and diversifying our product portfolio.

Impact
Our ultimate goal is to enhance global healthcare outcomes and drive down costs.